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Anoikis is a special form of apoptotic process that occurs in cells
in response to loss of adhesion to the extracellular matrix.1 It is a
fundamental cellular process for maintaining tissue homoeos-
tasis by removing displaced epithelial/endothelial cells and
preventing them from seeding to inappropriate sites.
Anoikis activation begins from the cell surface through
activation of the cell surface anoikis-initiating molecules such
as integrins, cadherins and death receptors. Loss of cell
adhesion to the extracellular matrix induces changes (e.g.,
conformation, dimer-/oligomer-ization or ligation with ligands)
of the cell surface anoikis-initiating molecules that initiate a
series of events leading to activation of either the caspase-8-
mediated extrinsic apoptosis signalling or the mitochondrial-
mediated intrinsic apoptosis signalling and consequent cell
death.2,3 For example, loss of engagement of cell surface
integrin with the extracellular matrix induces integrin oligomer
formation that leads to activation of the mitochondrial-
mediated intrinsic apoptosis signalling. Loss of cell contact
with the extracellular matrix induces ligation of the cell surface
death receptors with their ligands in the surrounding, leading
to activation of caspase-8-mediated extrinsic apoptosis
signalling. Resistance to anoikis is a hallmark of oncogenic
epithelial–mesenchymal transition and contributes promi-
nently to tumorigenesis4 and, in particular, to metastasis by
allowing survival of cancer cells that have invaded into the
blood or lymphatic circulation and thus facilitating their
metastatic spread to remote sites.
In 2014, we reported that expression of the transmembrane
mucin protein MUC1 plays an important role in epithelial
cancer cell resistance to anoikis.5 MUC1 is a very large (up to
500 kDa of molecular weight) and heavily glycosylated mucin
protein that is ubiquitously expressed in all normal epithelial
cells. MUC1 consists of a large and heavily glycosylated (up to
50% of the MUC1 molecular weight, mainly O-linked mucin
type glycans) extracellular domain, a transmembrane region
and a short cytoplasmic tail.6 In normal epithelium, MUC1 is
expressed exclusively on the apical side of the epithelia and
protrudes up to 10 times further above the cell surface than
other typical cell surface molecules.7 In epithelial cancer,
however, MUC1 expression is substantially increased (up to
10-fold), where it also loses its apical polarization and
becomes expressed over the entire cell surface. Overexpres-
sion of MUC1 is closely associated with high metastatic
potential and poor prognosis in cancer patients.8 Immunolo-
gical targeting of cancer-associated MUC1 has been under
intensive investigation as a strategy for cancer treatment.9
Both the MUC1 intracellular and extracellular domains were
found in the earlier study to contribute to resistance of
epithelial cancer cells to anoikis, but a pre-dominate influence
was seen to come from the MUC1 extracellular domain.5
In a recent article published inCell Death Discovery, shRNA
suppression of the Core 1 Gal-transferase (C1GT, T-synthase)
provides further insight into the action of MUC1 on epithelial
cancer cell resistance to anoikis.10 C1GT is a key glycosyl-
transferase in the biosynthesis of O-linked mucin-type
glycans.11 It is responsible for the formation of the Core 1
mucin-type carbohydrate structure (Galβ1,3GalNAcα-, Thom-
sen-Friedenreich, Tor TF antigen),12 which acts as a base for
further sugar chain elongation to form more complex (e.g.,
Core-2-associated) glycans.13 In this study, suppression of
C1GT in three human colon cancer cell lines was shown to
reduce the MUC1 O-glycosylation and substantially decrease
the size of MUC1 extracellular domain (by 425%). This
change significantly reduced the ability of the cancer cells to
initiate anoikis in response to anoikis culture (suspension
culture) of only the MUC1-positive cells but not the MUC1-
negative cells. It showed that reduction of the MUC1
O-glycosylation exposed many cell surface anoikis-initiating
molecules such as integrins, E-cadherin and Fas which
otherwise were concealed by the large and heavily glycosy-
lated MUC1 extracellular domain. Introduction of exogenous
Fas-L showed to increase caspase-8 activity and anoikis in the
MUC1-positive but not negative cells in comparison to their
non-C1GT-suppressed control cells. These discoveries sug-
gest an important role of MUC1 O-glycosylation in MUC1-
mediated epithelial cancer cell resistance to anoikis.
The extracellular matrix contains huge amount of large and
heavily glycosylated proteins (e.g., laminins, fibronectins).14 In
normal epithelium, many of these large extracellular matrix
glycoprotein interact with cell surface anoikis-initiating mole-
cules (e.g., fibronectin interactswith integrins). Disengagement
of these extracellular matrix glycoproteins with the anoikis-
initiating molecules during cell detachment from the extra-
cellular matrix likely represents a key sensor/trigger for
conformation change and activation of the cell surface
anoikis-initiating molecules in anoikis activation. MUC1
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extracellular domain shares two characters with these extra-
cellular matrix glycoproteins, it is large in size and is also
heavily modified by complex carbohydrate structures. It is likely
that the dense carbohydrate structures on MUC1 extracellular
domain in epithelial cancer cells may provide a similar ‘home’
microenvironment to the cell surface anoikis-initiating mole-
cules, as that provided by the extracellular matrix glycoprotein
in normal epithelium, and thus prevent activation of these
anoikis-initiating molecules during cell detachment from the
extracellular matrix (Figure 1). This action of MUC1 also
implies that other familymembers of the transmembranemucin
proteins (e.g., MUC4, MUC16 and so on), which are also huge
in size and heavily glycosylated with dense O-linked glycans
on their extracellular domains, may have similar influence on
anoikis of epithelial cancer cells as MUC1. This study
highlights the importance of cellular glycosylation in cell social
behaviour and activity and provides a good example of the
functional significance of cell surface glycosylation changes,
commonly occurred in all cancer cells, in cancer development
and progression.
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Figure 1 Model of the MUC1-mediated epithelial cancer cell resistance to anoikis. In normal epithelium, MUC1 is exclusively expressed on the apical side of the epithelia.
Loss of cell contact with the extracellular matrix breaks interaction of the cell surface anoikis-initiating molecules with the heavily glycosylated extracellular matrix proteins. This
results in conformation change and activation of these anoikis-initiating molecules, leading to apoptosis and cell death. In epithelial cancer cells, MUC1 is overexpressed over the
entire cell surface and interacts with the cell surface anoikis-initiating molecules. The dense carbohydrate structures on MUC1 extracellular domain provides a ‘home’
microenvironment to the anoikis-initiating molecules, similar to that provided by the extracellular matrix glycoproteins in normal epithelium, and thus prevent their activation and
cell death upon loss of cell–matrix contact
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